Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Zynerba Pharmaceuticals, Inc. | a16-14158_1ex99d1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 27, 2016
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware |
|
001-37526 |
|
26-0389433 |
(State or Other Jurisdiction of |
|
(Commission |
|
(I.R.S. Employer |
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 7.01 Regulation FD Disclosure
On June 27, 2016, Zynerba Pharmaceuticals, Inc. (the Company) issued a press release announcing positive top line results from its Phase 1 multiple rising dose clinical trial of its ZYN002 cannabidiol (CBD) gel in development for the treatment of epilepsy, osteoarthritis and Fragile X Syndrome. The Company also announced positive safety results in epilepsy patients in its single rising dose clinical trial of ZYN002 CBD gel and the initiation of its Phase 2 clinical trial of ZYN002 CBD gel in adult epilepsy patients with refractory focal seizures. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Item 7.01 (including Exhibit 99.1) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
EXHIBIT |
|
DESCRIPTION |
|
|
|
99.1 |
|
Press Release, dated June 27, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ZYNERBA PHARMACEUTICALS, INC. | ||
|
|
| |
Date: June 27, 2016 |
By: |
/s/ Suzanne Hanlon | |
|
|
Name: |
Suzanne Hanlon |
|
|
Title: |
Secretary, General Counsel and Vice President, Human Resources |